Bulk Manufacturer of Controlled Substances Application: AMRI Rensselaer, Inc., 38179 [2018-16635]
Download as PDF
<![CDATA[
38179
Federal Register / Vol. 83, No. 150 / Friday, August 3, 2018 / Notices
210 of the Commission’s Rules of
Practice and Procedure (19 CFR part
210).
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration in
accordance with 21 CFR 1301.33(a) on
or before October 2, 2018.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DRW, 8701
Morrissette Drive, Springfield, Virginia
22152.
DATES:
By order of the Commission.
Issued: July 30, 2018.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2018–16611 Filed 8–2–18; 8:45 am]
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
SUPPLEMENTARY INFORMATION:
[Docket No. DEA–392]
The Attorney General has delegated
his authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
Bulk Manufacturer of Controlled
Substances Application: AMRI
Rensselaer, Inc.
ACTION:
Notice of application.
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Assistant
Administrator of the DEA Diversion
Control Division (‘‘Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.33(a), this is notice that on June
25, 2018, AMRI Rensselaer, Inc., 33
Riverside Avenue, Rensselaer, New
York 12144 applied to be registered as
a bulk manufacturer of the following
basic classes of controlled substances:
Controlled substance
Drug code
Marihuana ........................................................................................................................................................................
Tetrahydrocannabinols ....................................................................................................................................................
Amphetamine ...................................................................................................................................................................
Lisdexamfetamine ............................................................................................................................................................
Pentobarbital ....................................................................................................................................................................
4-Anilino-N-phenethyl-4-piperidine (ANPP) .....................................................................................................................
Codeine ...........................................................................................................................................................................
Oxycodone .......................................................................................................................................................................
Hydromorphone ...............................................................................................................................................................
Hydrocodone ...................................................................................................................................................................
Meperidine .......................................................................................................................................................................
Morphine ..........................................................................................................................................................................
The company plans to manufacture
bulk controlled substances for use in
product development and for
distribution to its customers.
In reference to drug codes 7360
(marihuana) and 7370 (THC), the
company plans to bulk manufacture
these drugs as synthetics. No other
activities for these drug codes are
authorized for this registration.
Dated: July 23, 2018.
John J. Martin,
Assistant Administrator.
[FR Doc. 2018–16635 Filed 8–2–18; 8:45 am]
BILLING CODE 4410–09–P
amozie on DSK3GDR082PROD with NOTICES1
DEPARTMENT OF JUSTICE
Notice of Lodging of Proposed
Consent Decree Under the
Comprehensive Environmental
Response, Compensation and Liability
Act
On July 30, 2018, the Department of
Justice lodged a proposed consent
decree with the United States District
Court for the Central District of
California in the lawsuit entitled United
VerDate Sep<11>2014
18:26 Aug 02, 2018
Jkt 244001
States v. Honeywell International, Inc.,
Civil Action No. 2:18-cv-06556.
The United States filed this lawsuit
under the Comprehensive
Environmental Response,
Compensation, and Liability Act
(CERCLA) for the recovery of costs that
the United States incurred responding
to releases of hazardous substances at
Installation Restoration Program (IRP)
Site 50 at Vandenberg Air Force Base in
Santa Barbara County, California. The
consent decree requires the defendant
Honeywell International, Inc. to pay
$250,000 to the United States. In return,
the United States agrees not to sue the
defendant under sections 106 and 107 of
CERCLA at IRP Site 50 at Vandenberg
Air Force Base.
The publication of this notice opens
a period for public comment on the
proposed consent decree. Comments
should be addressed to the Assistant
Attorney General, Environment and
Natural Resources Division, and should
refer to United States v. Honeywell
International, Inc., D.J. Ref. No. 90–11–
3–10477/5. All comments must be
submitted no later than thirty (30) days
after the publication date of this notice.
PO 00000
Frm 00064
Fmt 4703
Sfmt 4703
7360
7370
1100
1205
2270
8333
9050
9143
9150
9193
9230
9300
Schedule
I
I
II
II
II
II
II
II
II
II
II
II
Comments may be submitted either by
email or by mail:
To submit
comments:
Send them to:
By email .......
pubcomment-ees.enrd@
usdoj.gov.
Assistant Attorney General,
U.S. DOJ—ENRD, P.O.
Box 7611, Washington, DC
20044–7611.
By mail .........
During the public comment period,
the proposed consent decree may be
examined and downloaded at this
Justice Department website: https://
www.justice.gov/enrd/consent-decrees.
We will provide a paper copy of the
proposed consent decree upon written
request and payment of reproduction
costs. Please mail your request and
payment to: Consent Decree Library,
U.S. DOJ—ENRD, P.O. Box 7611,
Washington, DC 20044–7611.
Please enclose a check or money order
for $5.25 (25 cents per page
E:\FR\FM\03AUN1.SGM
03AUN1
]]>Agencies
[Federal Register Volume 83, Number 150 (Friday, August 3, 2018)]
[Notices]
[Page 38179]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-16635]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Bulk Manufacturer of Controlled Substances Application: AMRI
Rensselaer, Inc.
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic classes, and
applicants therefore, may file written comments on or objections to the
issuance of the proposed registration in accordance with 21 CFR
1301.33(a) on or before October 2, 2018.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DRW,
8701 Morrissette Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION:
The Attorney General has delegated his authority under the
Controlled Substances Act to the Administrator of the Drug Enforcement
Administration (DEA), 28 CFR 0.100(b). Authority to exercise all
necessary functions with respect to the promulgation and implementation
of 21 CFR part 1301, incident to the registration of manufacturers,
distributors, dispensers, importers, and exporters of controlled
substances (other than final orders in connection with suspension,
denial, or revocation of registration) has been redelegated to the
Assistant Administrator of the DEA Diversion Control Division
(``Assistant Administrator'') pursuant to section 7 of 28 CFR part 0,
appendix to subpart R.
In accordance with 21 CFR 1301.33(a), this is notice that on June
25, 2018, AMRI Rensselaer, Inc., 33 Riverside Avenue, Rensselaer, New
York 12144 applied to be registered as a bulk manufacturer of the
following basic classes of controlled substances:
------------------------------------------------------------------------
Controlled substance Drug code Schedule
------------------------------------------------------------------------
Marihuana.......................... 7360 I
Tetrahydrocannabinols.............. 7370 I
Amphetamine........................ 1100 II
Lisdexamfetamine................... 1205 II
Pentobarbital...................... 2270 II
4-Anilino-N-phenethyl-4-piperidine 8333 II
(ANPP).
Codeine............................ 9050 II
Oxycodone.......................... 9143 II
Hydromorphone...................... 9150 II
Hydrocodone........................ 9193 II
Meperidine......................... 9230 II
Morphine........................... 9300 II
------------------------------------------------------------------------
The company plans to manufacture bulk controlled substances for use
in product development and for distribution to its customers.
In reference to drug codes 7360 (marihuana) and 7370 (THC), the
company plans to bulk manufacture these drugs as synthetics. No other
activities for these drug codes are authorized for this registration.
Dated: July 23, 2018.
John J. Martin,
Assistant Administrator.
[FR Doc. 2018-16635 Filed 8-2-18; 8:45 am]
BILLING CODE 4410-09-P
